Investigation on the effectiveness of histidine copper treatment of Menkes disease patients

Investigation on the effectiveness of histidine copper treatment of Menkes disease patients - Investigation on the effectiveness of histidine copper treatment of Menkes disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030626

Enrollment

Registered

2017-12-28

Start date

2014-11-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menkes disease

Interventions

Weekly,subcutaneous injection of histidine copper (750microgram once) is performed three times per week.It is continued every week until the end of the research during the research period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who have written explanation and consent from patients who want family history of histidine copper treatment in Menkes disease patients

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
development	—

Secondary

Measure	Time frame
The presence or absence of spasm	—

Countries

Japan

Contacts

Public ContactTokiko Fukuda

Hamamatsu University School of Medicine Department of Pediatrics

toki-fkd@hama-med.ac.jp053-435-2638

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026